Yael Cohen, MD, on Background for and Key Findings from the Updated CARTITUDE-2 Trial With Cilta-Cel in Refractory Myeloma


CancerNetwork®, sat down with Yael Cohen, MD, to discuss the research that lead up to the phase 2 CARTITUDE-2 trial, examining the use of ciltacabtagene autoleucel for those with lenalidomide–refractory multiple myeloma

In an interview with CancerNetwork®, Yael Cohen, MD, a senior physician in the Department of Hematology at Tel-Aviv Sourasky Medical Center, lent context to the updated findings of the phase 2 CARTITUDE-2 trial (NCT04133636), which were presented at the 2021 American Society for Hematology Annual Meeting & Exposition, examining ciltacabtagene autoleucel (cilta-cel) in patients with lenalidomide (Revlimid)–refractory multiple myeloma.1

The CAR T-cell therapy was assessed in the phase 1b/2 CARTITUDE-1 trial (NCT03548207), which highlighted an overall response rate of 97.9% with a stringent complete response rate of 80.4% after a median follow-up of 18 months.2 The duration of these responses were examined in CARTITUDE-2, the results of which very encouraging, according to Cohen.


CARTITUDE-1 was testing cilta-cel in a very heavily pretreated group of patients; these were patients with relapsed/refractory myeloma after a median of 6 lines of therapy. These patients were known to have an expected very poor prognosis with any other alternatives available. Their overall response rate in CARTITUDE-1 was close to 98%. [Therefore], this was really a game changer. Actually [at] this [year's] ASH, there [were] the updated and very exciting results also on the durability of [these responses]. At 2 years, over 60% of the patients are still maintaining a response and the PFS was not reached.

Because they offer these attractive, exciting results—as [with] other drugs in myeloma—this is [being] taken to earlier lines of treatment; this is the CARTITUDE-2 trial. TheThis trial actually has several different cohorts and [in] cohort A, which is the study I'm presenting this evening, some patients [had] 1 to 3 lines of [prior] therapy. These are earlier patients [with] 20 patients [included]. These patients were on and then refractory to an [immunomodulatory agent] and proteosome inhibitors. [Additionally], 95% also had an alkylating agent [and] 65% had daratumumab [Darzalex]. These patients were also lenalidomide [Revlimid] refractory, so these are tough patients to get durable responses [in], as well. This was the population, and they got a single infusion of cilta-cel in this study.


  1. Cohen YC, Cohen AD, Delforge M, et al. Efficacy and safety of ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy, in lenalidomide-refractory patients with progressive multiple myeloma after 1-3 prior lines of therapy: updated results from CARTITUDE-2. Presented at: 2021 ASH Annual Meeting; December 11-13, 2021; Atlanta, GA. Poster 3866.
  2. Usmani SZ, Berdeja JG, Madduri D, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed/refractory multiple myeloma (R/R MM): updated results from CARTITUDE-1. J Clin Oncol. 2021,39(suppl 15):abstr 8005. doi:10.1200/JCO.2021.39.15_suppl.8005
Related Videos
Considering cystectomy in patients with bladder cancer may help with managing the shortage of Bacillus Calmette-Guerin, according to Joshua J. Meeks, MD, PhD, BS.
Ursula Linne-McLaren, RN, an expert on multiple myeloma
Amir Ali, PharmD, BCOP, an expert on multiple myeloma
Amir Ali, PharmD, BCOP, an expert on multiple myeloma
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Patients with locally advanced or metastatic urothelial cancer and visceral disease may particularly benefit from enfortumab vedotin plus pembrolizumab, according to Amanda Nizam, MD.
Amir Ali, PharmD, BCOP, an expert on multiple myeloma
Related Content